{"id":130791,"date":"2022-06-24T04:45:01","date_gmt":"2022-06-24T08:45:01","guid":{"rendered":"https:\/\/44.250.171.167\/?p=130791"},"modified":"2022-10-06T04:21:59","modified_gmt":"2022-10-06T08:21:59","slug":"iol-chemicals-and-pharmaceuticals-limited-q4-fy22-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/iol-chemicals-and-pharmaceuticals-limited-q4-fy22-earnings-conference-call-insights\/","title":{"rendered":"IOL Chemicals and Pharmaceuticals Limited Q4 FY22 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"IOL Chemicals and Pharmaceuticals Limited Q4 FY22 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/HCB5WuVf8_E?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<h2><strong>Key highlights from IOL Chemicals and Pharmaceuticals Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/IOLCP\/\">IOLCP<\/a>) Q4 FY22 Earnings Concall<\/strong><\/h2>\n<p><strong>\u00a0<\/strong><\/p>\n<h3><strong>Management Update:<\/strong><\/h3>\n<ul>\n<li>IOLCP is optimistic on its pharma segment as capacity for other potentially large projects are ready. Gross margin in this segment is expected to improve with improved business mix.<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<h3><strong>Q&amp;A Highlights:<\/strong><\/h3>\n<p><strong>Dhaval Shah &#8211; Svan Investment &#8211; Analyst<\/strong><\/p>\n<ul>\n<li>Reason for chemical business reporting loss at the EBIT level and outlook going forward?<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>Primary product ethyl acetate depends on acetic acid that comes all from exports.\n<ul>\n<li>Had a lot of volatility in acetic acid pricing.<\/li>\n<\/ul>\n<\/li>\n<li>The numbers should be seen from a quarterly or yearly perspective since the time of placing the order, to utilization of RM takes at least two months.<\/li>\n<li>On an annual basis, IOLCP will continue to make 6-8% EBITDA in this business.<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Dhaval Shah &#8211; Svan Investment \u2013 Analyst<\/strong><\/p>\n<ul>\n<li>Change in capacity in the chemical business today vs. the next three years?<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>Existing capacity is about 1 lakh tons from Ethyl Acetate.\n<ul>\n<li>Over the next couple of years, will have marginal expansion of about 20%, 25%.<\/li>\n<li>This will be through minor modification of plants.<\/li>\n<\/ul>\n<\/li>\n<li>In the process of identifying new products for which capacities will be added.\n<ul>\n<li>Should come on line around next year.<\/li>\n<\/ul>\n<\/li>\n<li>Most of chemicals business growth will come from non-ethyl acetate products.<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Dhaval Shah &#8211; Svan Investment \u2013 Analyst<\/strong><\/p>\n<ul>\n<li>Reason for Ibuprofen volumes being less in 4Q22?<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>The overstocking from previous year from some key accounts has still not been eliminated.<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Rohit Suresh &#8211; Samatva Investments &#8211; Analyst<\/strong><\/p>\n<ul>\n<li>Demand in the regulated market for Ibu?<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>Assets are running at 70% or so utilization.\n<ul>\n<li>Should add a few percentage points to this in coming quarters.<\/li>\n<\/ul>\n<\/li>\n<li>IOLCP might not sell at full capacity, but at a higher capacity than the previous year.<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Rohit Suresh &#8211; Samatva Investments \u2013 Analyst<\/strong><\/p>\n<ul>\n<li>Would Ibu prices increase in FY23, once the overstocking issue gets solved.<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>It should probably go up.\n<ul>\n<li>Input cost of all RMs are going up, energy costs doubling, Russia-Ukraine war etc.<\/li>\n<li>Once input costs go up, the price of final product also goes up, probably in a phased lag.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Ranvir Singh &#8211; Sunidhi Securities \u2013 Analyst<\/strong><\/p>\n<ul>\n<li>Ethyl Acetate business split geographically; India vs. export.<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>Ethyl Acetate business primarily is still domestic for IOLCP.<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Chirag Fialoke &#8211; Ratna Traya Capital \u2013 Analyst<\/strong><\/p>\n<ul>\n<li>Ibuprofen volume for FY22 vs. FY21?<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>IOLCP declined by almost a 1000 tons for the year.<\/li>\n<li>Volumes were closer to the range of 8,000 tons, 8,300 tons.<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Anupam Agarwal &#8211; Lucky Investment Managers \u2013 Analyst<\/strong><\/p>\n<ul>\n<li>Paracetamol capacity and volume for IOLCP?<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>Currently having a capacity of 1,800 tons a year.<\/li>\n<li>Expect this to be about 3,600 tons by the end of FY23.<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Anupam Agarwal &#8211; Lucky Investment Managers \u2013 Analyst<\/strong><\/p>\n<ul>\n<li>Reason for the jump of INR185 crore in other non-current assets in consolidated balance sheet?<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>The FD that was in the short-term has been moved into long-term, which is sitting in other non-current assets.<\/li>\n<\/ul>\n<p><strong>\u00a0 \u00a0<\/strong><\/p>\n<p><strong>Aditya Shah &#8211; Individual Investor \u2013 Analyst<\/strong><\/p>\n<ul>\n<li>Expected margins on the API non-ibuprofen business?<\/li>\n<\/ul>\n<p><strong>Sanjay Chaturvedi &#8211; Chief Executive Officer<\/strong><\/p>\n<ul>\n<li>Current margins are in the single digits.\n<ul>\n<li>Asset utilization still continues to be low in the range of 50%, 60%.<\/li>\n<\/ul>\n<\/li>\n<li>Expects to take it to 75%, 80% level in the next 12-18 months.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from IOL Chemicals and Pharmaceuticals Limited (IOLCP) Q4 FY22 Earnings Concall \u00a0 Management Update: IOLCP is optimistic on its pharma segment as capacity for other potentially large projects are ready. Gross margin in this segment is expected to improve with improved business mix. \u00a0 Q&amp;A Highlights: Dhaval Shah &#8211; Svan Investment &#8211; Analyst [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747,5753],"tags":[1115],"class_list":["post-130791","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","category-industrials","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":137010,"url":"https:\/\/alphastreet.com\/india\/iol-chemicals-and-pharmaceuticals-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":130791,"position":0},"title":"IOL Chemicals and Pharmaceuticals Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 21, 2022","format":false,"excerpt":"Key highlights from IOL Chemicals and Pharmaceuticals Limited (IOLCP) Q2 FY23 Earnings Concall Q&A Highlights: [00:12:26] Venkat of 3Sigma Financials asked about the growth numbers for 3Q23 and FY24. Sanjay Chaturvedi CEO said that in FY23, IOLCP is going to show some muted growth in the single-digits, but in FY24,\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":144444,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-iol-chemicals-pharmaceuticals-for-q4-fy23\/","url_meta":{"origin":130791,"position":1},"title":"Earnings Summary Of IOL Chemicals &#038; Pharmaceuticals For Q4 FY23","author":"Hardik Bhandare","date":"April 28, 2023","format":false,"excerpt":"IOL Chemicals & Pharmaceuticals Limited is an Indian-based pharmaceutical company engaged in the manufacturing and marketing of bulk drugs and organic chemicals. The company has a diverse product portfolio, including Ibuprofen, Metformin, Lamotrigine, and various other APIs and intermediates used in the pharmaceutical, food, and animal feed industries. IOL Chemicals\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":129589,"url":"https:\/\/alphastreet.com\/india\/jubilant-ingrevia-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":130791,"position":2},"title":"Jubilant Ingrevia Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 18, 2022","format":false,"excerpt":"https:\/\/youtu.be\/q-jII_ukXcc Key highlights from Jubilant Ingrevia Ltd (JUBLINGREA) Q4 FY22 Earnings Concall Management Update: JUBLINGREA said it recorded the highest ever revenue of INR4,949 crore and highest ever EBITDA of INR863 crore in FY22, which is a growth of 42% and 38%, respectively over FY21. JUBLINGREA also commented that estimated\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127005,"url":"https:\/\/alphastreet.com\/india\/jubilant-ingrevia-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":130791,"position":3},"title":"Jubilant Ingrevia Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 2, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=VEV5IjVrTNI Key highlights from Jubilant Ingrevia Ltd (JUBLINGREA) Q3 FY22 Earnings Concall Management Update: JUBLINGREA commented that with its capex plans shaping up, it is on course of doubling the revenue by FY26 from the base of FY21. For FY23 capex is expected to be around INR300 crore. Q&A Highlights:\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":152109,"url":"https:\/\/alphastreet.com\/india\/iol-chemicals-31-rise-in-profits\/","url_meta":{"origin":130791,"position":4},"title":"IOL Chemicals &#038; Pharmaceuticals Ltd Q1FY24; 31% rise in Profits","author":"Hardik Bhandare","date":"August 9, 2023","format":false,"excerpt":"IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market. Financial Results IOL Chemicals & Pharmaceuticals Ltd reported Revenues for Q1FY24 of \u20b9563.00 Crores down from \u20b9565.00 Crore year on year, a\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-479.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-479.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-479.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-479.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-479.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-479.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170887,"url":"https:\/\/alphastreet.com\/india\/laxmi-organic-q1-fy26-earnings-results\/","url_meta":{"origin":130791,"position":5},"title":"Laxmi Organic Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"September 3, 2025","format":false,"excerpt":"Laxmi Organic Industries Limited was established in 1989 and is in the business of specialty chemicals. The Company primarily manufactures Ethyl Acetate, Acetic Acid and Diketene Derivative Products (DDP). DDP is a specialty chemical group, the technology and business of which has been acquired by the company from Clariant Chemicals\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Laxmi Organic Industries Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=130791"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130791\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=130791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=130791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=130791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}